STOCK TITAN

Cidara Therapeutics Inc - CDTX STOCK NEWS

Welcome to our dedicated news page for Cidara Therapeutics (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cidara Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cidara Therapeutics's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.55%
Tags
none
Cidara Therapeutics Inc

Nasdaq:CDTX

CDTX Rankings

CDTX Stock Data

83.37M
76.81M
7.53%
30.91%
0.2%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
San Diego

About CDTX

cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.